Department of Women and Children's Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, London, United Kingdom; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom; Children's Allergy Service, Evelina London Children's Hospital, Guy's and St Thomas' Hospital, London, United Kingdom; Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom.
Department of Women and Children's Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, London, United Kingdom; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom; Children's Allergy Service, Evelina London Children's Hospital, Guy's and St Thomas' Hospital, London, United Kingdom.
J Allergy Clin Immunol. 2020 Aug;146(2):344-355. doi: 10.1016/j.jaci.2020.03.035. Epub 2020 Apr 18.
Oral food challenge (OFC) is the criterion standard to assess peanut allergy (PA), but it involves a risk of allergic reactions of unpredictable severity.
Our aim was to identify biomarkers for risk of severe reactions or low dose threshold during OFC to peanut.
We assessed Learning Early about Peanut Allergy study, Persistance of Oral Tolerance to Peanut study, and Peanut Allergy Sensitization study participants by administering the basophil activation test (BAT) and the skin prick test (SPT) and measuring the levels of peanut-specific IgE, Arachis hypogaea 2-specific IgE, and peanut-specific IgG4, and we analyzed the utility of the different biomarkers in relation to PA status, severity, and threshold dose of allergic reactions to peanut during OFC.
When a previously defined optimal cutoff was used, the BAT diagnosed PA with 98% specificity and 75% sensitivity. The BAT identified severe reactions with 97% specificity and 100% sensitivity. The SPT, level of Arachis hypogaea 2-specific IgE, level of peanut-specific IgE, and IgG4/IgE ratio also had 100% sensitivity but slightly lower specificity (92%, 93%, 90%, and 88%, respectively) to predict severity. Participants with lower thresholds of reactivity had higher basophil activation to peanut in vitro. The SPT and the BAT were the best individual predictors of threshold. Multivariate models were superior to individual biomarkers and were used to generate nomograms to calculate the probability of serious adverse events during OFC for individual patients.
The BAT diagnosed PA with high specificity and identified severe reactors and low threshold with high specificity and high sensitivity. The BAT was the best biomarker for severity, surpassed only by the SPT in predicting threshold. Nomograms can help estimate the likelihood of severe reactions and reactions to a low dose of allergen in individual patients with PA.
口服食物挑战(OFC)是评估花生过敏(PA)的标准方法,但它涉及不可预测严重程度的过敏反应风险。
我们旨在确定在花生口服食物挑战期间严重反应或低剂量阈值的风险的生物标志物。
我们通过进行嗜碱性粒细胞激活试验(BAT)和皮肤点刺试验(SPT),并测量花生特异性 IgE、花生球蛋白 2 特异性 IgE 和花生特异性 IgG4 的水平,评估了 Learning Early about Peanut Allergy 研究、 Persistance of Oral Tolerance to Peanut 研究和 Peanut Allergy Sensitization 研究的参与者,并分析了不同生物标志物在与 PA 状态、严重程度和 OFC 期间花生过敏反应的阈值剂量的关系中的效用。
当使用先前定义的最佳截止值时,BAT 以 98%的特异性和 75%的灵敏度诊断 PA。BAT 以 97%的特异性和 100%的灵敏度识别严重反应。SPT、花生球蛋白 2 特异性 IgE 水平、花生特异性 IgE 水平和 IgG4/IgE 比值也具有 100%的敏感性,但特异性略低(分别为 92%、93%、90%和 88%),以预测严重程度。反应阈值较低的参与者在体外对花生的嗜碱性粒细胞激活更高。SPT 和 BAT 是阈值的最佳个体预测因子。多变量模型优于单个生物标志物,并用于生成列线图,以计算个体患者在 OFC 期间发生严重不良事件的概率。
BAT 以高特异性诊断 PA,并以高特异性和高灵敏度识别严重反应者和低阈值。BAT 是严重程度的最佳生物标志物,仅在预测阈值方面被 SPT 超越。列线图可以帮助估计个体 PA 患者发生严重反应和低剂量过敏原反应的可能性。